Want to join the conversation?
Biotechnology company $CARA announced positive topline results from its Phase 2a trial of oral CR845 in patients with osteoarthritis of the knee or hip. All tablet strengths were generally well tolerated with no drug-related SAEs. Based on these results, $CARA plans to conduct a larger double-blind, placebo-controlled Phase 2b trial in 2016.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!